Crestor Label Lends Validity To Controversial C-Reactive Protein Test
This article was originally published in The Pink Sheet Daily
Executive Summary
Some cardiologists dispute aspects of new label for primary prevention of heart disease.
You may also be interested in...
FDA Plows Out: Telecommuting Triumphs As Blizzard Puts A Hole In CDER's Roof
PDUFA user fee dates could slip by as much as five business days because of the blizzards that shut down the federal government in Washington, D.C., Feb. 8-11
FDA Plows Out: Telecommuting Triumphs As Blizzard Puts A Hole In CDER's Roof
PDUFA user fee dates could slip by as much as five business days because of the blizzards that shut down the federal government in Washington, D.C., Feb. 8-11
As Crestor Patent Trial Nears, Generic Firms Seek To Block AstraZeneca Subsidiary From Suit
Defendants in infringement case claim AstraZeneca Pharmaceuticals LP has no rights to the patent at issue.